Human parathyroid hormone (1-34) [hPTH(1-34)] is a new class of skeletal anabolic agents that stimulates osteoblastic bone formation and has already been approved for the treatment of osteoporotic patients who are at high risk for fractures or who have been intolerant of previous osteoporosis therapy. Here, PTH is linked to osteoporosis.